School of Paediatrics and Child Health Research, Princess Margaret Hospital, University of Western Australia, Perth, WA, Australia.
Clin Exp Allergy. 2009 Dec;39(12):1801-14. doi: 10.1111/j.1365-2222.2009.03368.x.
With the advent of the hygiene hypothesis, probiotics have provided an avenue of hope in curbing the allergic epidemic. The initial enthusiasm has been tempered by recognition of the inherent complexities of this approach. This review examines the current clinical evidence and practical issues in using probiotics and related products, for the prevention and treatment of allergic disease. So far, probiotics have shown more promise, albeit limited, in the primary prevention of allergic disease rather than in the treatment of established disease. These effects have largely been limited to the prevention of early childhood conditions such as eczema, with no consistent effects on other allergic outcomes. There is emerging evidence that clinical effects may be strain specific, but again these findings have been inconsistent. While there have been several meta-analyses to examine probiotics in both the prevention and the treatment of allergic disease, these have been hampered by significant heterogeneity between studies, including wide variations in the strains used, the methods and timing of administration and the age and assessment of allergic outcomes. In any case, these have also become outdated by a series of new studies published in the last year. Although it is not yet clear exactly how the growing number of new studies will modify the results of meta-analyses, it is likely that these will add yet further heterogeneity that will continue to make interpretation of pooled data difficult. At this stage, the effects of prebiotics, synbiotics and postbiotics are even less clear. Thus, while there is little doubt that microbiota modulate immune development and can prevent the allergic phenotype, the optimal way of achieving this is far from clear. Given the current level of evidence, it is not appropriate to recommend prebiotics/probiotics/synbiotics or postbiotics as a part of standard therapy or for the prevention of any allergic conditions. Further studies are needed to address the growing speculation that supplementation with a single probiotic strain may be oversimplistic and that approaches that have a more global effect on colonization may be warranted.
随着卫生假说的出现,益生菌为抑制过敏流行提供了希望。人们认识到这种方法的固有复杂性,最初的热情有所降温。这篇综述考察了使用益生菌和相关产品预防和治疗过敏性疾病的当前临床证据和实际问题。到目前为止,益生菌在预防过敏性疾病方面显示出更大的希望,尽管这种希望有限,但在治疗已确诊的疾病方面则不然。这些作用主要限于预防婴幼儿湿疹等早期疾病,对其他过敏结果没有一致的影响。有新的证据表明,临床效果可能与菌株特异性有关,但这些发现也不一致。虽然已经有几项荟萃分析研究了益生菌在预防和治疗过敏性疾病中的作用,但这些分析受到研究之间显著异质性的阻碍,包括使用的菌株、给药方法和时间以及评估过敏结果的年龄等方面存在广泛差异。在任何情况下,这些分析也因去年发表的一系列新研究而变得过时。尽管目前还不清楚新的研究数量的增加将如何改变荟萃分析的结果,但很可能会增加更多的异质性,这将继续使汇总数据的解释变得困难。在现阶段,对于益生元、合生元和后生元的作用甚至更不清楚。因此,尽管越来越多的研究表明微生物组调节免疫发育并可以预防过敏表型,但实现这一目标的最佳方式还远不清楚。鉴于目前的证据水平,不建议将益生元/益生菌/合生元或后生元作为标准治疗或预防任何过敏的一部分。需要进一步的研究来解决日益增长的猜测,即补充单一益生菌菌株可能过于简单化,而对定植具有更广泛影响的方法可能是合理的。
Clin Exp Allergy. 2009-12
Nestle Nutr Workshop Ser Pediatr Program. 2009
J Leukoc Biol. 2011-1-13
J Allergy Clin Immunol. 2007-8
Clin Exp Allergy. 2006-5
J Paediatr Child Health. 2013-9
Adv Biochem Eng Biotechnol. 2008
Allergol Int. 2017-9-1
J Clin Med. 2024-12-24
J Food Drug Anal. 2017-2-13
Microb Ecol Health Dis. 2016-6-23
Iran J Pediatr. 2014-2
Pharmaceuticals (Basel). 2012-7-6
Asia Pac Allergy. 2013-7
Ital J Pediatr. 2013-7-29
World Allergy Organ J. 2013-1-31
Nat Immunol. 2011-4